Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Philip J. Mease

Philip J. Mease

Rheumatologist, Swedish Medical Center; POETYK trial investigator

Appears in 1 story

Stories

First TYK2 inhibitor reaches FDA decision for psoriatic arthritis

New Capabilities

Active clinical researcher in psoriatic arthritis therapeutics

For most of the past decade, people with psoriatic arthritis who wanted a pill had one real choice: Janus kinase (JAK) inhibitors. The FDA slapped those drugs with its strongest safety warning in 2021, after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death.

Updated May 30